导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.35% | 1022/1840 |
| 近一周 | -1.80% | 1010/2029 |
| 近一月 | -3.46% | 906/2018 |
| 近一季 | -6.59% | 945/1966 |
| 近半年 | -2.13% | 762/1877 |
| 近一年 | 1.03% | 949/1753 |
| 近两年 | 42.97% | 744/1324 |
| 近三年 | 25.80% | 519/1010 |
| 成立以来 | 12.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.73% 3380/4961 |
11.94% 2264/5312 |
- - |
- - |
| 2025 | 18.67% 2294/4813 |
-1.11% 2583/3635 |
2.02% 1938/4076 |
17.68% 2454/4524 |
-0.05% 2329/4813 |
| 2024 | 15.35% 941/3463 |
2.90% 673/2808 |
-1.12% 940/3014 |
15.63% 1670/3129 |
-1.95% 1900/3463 |
| 2023 | -9.65% 1210/2656 |
4.07% 1054/2280 |
-3.99% 998/2385 |
-3.40% 920/2515 |
-6.39% 1750/2655 |
| 2022 | -20.18% 944/2207 |
-14.49% 951/1919 |
6.63% 647/2016 |
-13.71% 953/2113 |
1.44% 1264/2208 |
| 2021 | -4.06% 940/1822 |
-3.29% 793/1255 |
4.14% 917/1330 |
-5.89% 873/1466 |
1.22% 980/1822 |
| 2020 | - - |
- - |
- - |
4.95% 939/1164 |
12.69% 442/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 泰康沪深300ETF联接C VS. 长安沪深300非周期A(740101) |